Nausea and vomiting are the two most common side effects associated with cancer chemotherapy, and are referred to as chemotherapy induced nausea and vomiting (CINV).  CINV significantly affects the treatment of patients undergoing chemotherapy. Two major subtypes of CINV are acute CINV (occurs within 24 hours of chemotherapy) and delayed CINV (occurs between 24 hours and five days after treatment). Aloxi (palonosetron), Zofran generic (ondansetron), Kytril generic (granisetron), Emend (aprepitant) and Akynzeo (netupitant-palonosetron FDC) are the examples of currently available drugs to manage both CINV subtypes. In coming years, the CINV drugs market is expected to witness the introduction of two new drugs, namely, SUSTOL (extended release generic granisetron) and rolapitant.
 
The world is witnessing a continuous rise in the incidence of various types of cancer, which results in increasing number of patients undergoing chemotherapy. According to the online cancer database GLOBOCAN by the International Agency for Research on Cancer (IARC), globally 14.1 million people were diagnosed with cancer (excluding non-melanoma skin cancer) in 2012 as compared to 12.7 million in 2008. The incidence rate is projected to reach 15.2 million and 17.1 million in 2015 and 2020, respectively. These facts indicate that growing incidence of various types of cancer is likely to induce oncologists to prescribe chemotherapy to their patients for the effective treatment of cancer, thereby driving the CINV drugs market. Usually 25% to 30% patients with cancer receive chemotherapy as a treatment option and 70% to 80% of these patients undergoing chemotherapy exhibit nausea and vomiting as major symptoms.
 
The approval of new drugs such as rolapitant and SUSTOL (APF-530) would also drive the growth of the CINV drugs market during the forecast period from 2014 to 2020. These pipeline drugs have shown better efficacy than existing drugs during their clinical study. Therefore, the anticipated launch of these more efficacious pipeline drugs during the projected period is likely to encourage physicians to prescribe these new drugs over existing drugs. However, the patent expiry of leading drugs Aloxi and Emend are expected to have significant impact on the revenue of overall CINV drugs market during the forecast period from 2014 to 2020.
 
North America was the largest regional market for CINV drugs in 2013 in terms of revenue and is expected to retain its position throughout the forecast period, primarily due to the anticipated approval of rolapitant and SUSTOL in 2015 and 2016, respectively. Europe represented the second largest market for CINV drugs after North America in 2013. The launch of CINV pipeline drugs in Europe is expected to be a year later than in North America, given the delays on the past launches of CINV drugs such as Aloxi and Emend. The high incidence of various types of cancer in Asia-Pacific and Rest of the World (RoW) represents both these regions as potential markets for CINV drugs. The economic emergence of countries such as India and China, along with their continuously improving health care infrastructure, is expected to play a key role in driving the CINV market growth in Asia-Pacific region.
 
GlaxoSmithKline plc, Helsinn Holding S.A., Heron Therapeutics, Inc., Merck & Co., Inc. and Tesaro, Inc. are among the major players operating in the CINV drugs market. In addition to these players, the market is also characterized by a number of generic manufacturers such as Baxter Healthcare, Barr Laboratories, Inc., Sun Pharma, Sandoz (Novartis AG), Mylan Pharmaceuticals, Inc., Orchid Healthcare and Teva Pharmaceuticals.
 
 

Global Chemotherapy-Induced Nausea And Vomiting Market: Brief Overview

Chemo therapy induced nausea and vomiting significantly affects the treatment of patients who are suffering from cancer and undergoing chemotherapy. Nausea and vomiting are the side effects which are commonly associated with chemotherapy and may occur within 24 hours of chemotherapy or between 24 hours and five days after chemotherapy. With increasing and continuous rise in the number of people suffering from cancer and therefore an increasing number of people undergoing chemotherapy, it is estimated that the global CINV market will witness a healthy growth in the future. Approximately 14.1 million people across the globe have been diagnosed with cancer in 2012 as per and online cancer database GLOBALCAN. This market is anticipated to reach an evaluation of US$1.88 bn by 2020.

As CINV can be an obstruction to the progress of cancer patients undergoing chemotherapy, the demand for CINV drugs is increasing rapidly. It has become absolutely crucial for oncologists to prescribe the correct drug for treating chemotherapy-induced nausea and vomiting to alleviate the discomfort and pain among patients as well as to be able to carry out further treatment without any delay.

Global Chemotherapy-Induced Nausea And Vomiting Pipeline Drugs Market:  Trends and Opportunities

At present the effect of drugs which are available in the market in order to manage chemotherapy-induced nausea and vomiting (CINV) are: Aloxi (palonosetron), Zofran generic (ondansetron), Kytril generic (granisetron), Emend (aprepitant) and Akynzeo (netupitant-palonosetron FDC). It is expected that in the years to come two new drugs will be introduced. They are: rolapitant and SUSTOL (APF-530). The approval of drugs such as rolapitant and SUSTOL is driving the growth of the global chemotherapy-induced nausea and vomiting drugs market. With several new drugs in the pipeline, it is expected that the future of the chemotherapy induced nausea and vomiting drugs market will be bright, and it will encourage doctors to prescribe new drugs. The approval of new drugs will also help the market to grow. On the other hand, the patent expiry of leading drugs such as Emend, Aloxi, and others is expected to negatively impact the revenue of the chemotherapy-induced nausea and vomiting drugs market.

Global Chemotherapy-Induced Nausea And Vomiting Market: Geographical Analysis

On the basis of geography, the global chemotherapy-induced nausea and vomiting drugs market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. Of these, North America has been leading in terms of revenue within the CINV drugs market. This is on account of the approval of important drugs such as Rolapitant and SUSTOL. The launch of pipeline drugs for chemotherapy-induced nausea and vomiting in Europe is also expected to drive the market in Europe. Apart from these two regions the growing incidences of various types of cancer in the Asia Pacific as well as the Rest of the World will ensure that both of these regions will be promising markets for  chemotherapy induced nausea and vomiting drugs market. Emerging economies such as China and India are striving to achieve improved and efficient healthcare infrastructure. This in turn is expected to bode well for the chemotherapy-induced nausea and vomiting drugs market in the Asia Pacific region.

Global Chemotherapy-Induced Nausea And Vomiting Drugs Market: Companies Mentioned

The global chemotherapy-induced nausea and vomiting drugs market is characterized by a number of generic manufacturers in the vendor landscape. They are: Barr Laboratories, Inc., Baxter Healthcare, Sun Pharma, Teva Pharmaceuticals Mylan Pharmaceuticals, Inc., Sandoz (Novartis AG), and Orchid Healthcare. Some of the other important companies within the global chemotherapy induced nausea and vomiting drugs market are: Heron Therapeutics, Inc., Helsinn Holding S.A., Merck & Co., Inc., GlaxoSmithKline plc,  and Tesaro, Inc.

.